The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

AbbVie, Danaher, and Thermo Fisher Scientific are the three Biotech stocks to watch today, according to MarketBeat’s stock ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study.

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Ozempic is given as an injection under your skin. Ozempic can be prescribed for adults with type 2 diabetes to: To learn more about Ozempic’s approved uses, see the “What is Ozempic used for?” ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of hyaluronidase enzymes, which help convert IV drugs into injectable versions.

“Previously, patients thought to be eligible for LAIs — also reflected in past guidelines — were chronically ill patients, those with multiple relapses, established nonadherence, or patients ...